# A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer

> **NCT00423410** · PHASE1 · COMPLETED · sponsor: **EpiCept Corporation** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** EPC2407 (crinobulin)

## Key facts

- **NCT ID:** NCT00423410
- **Lead sponsor:** EpiCept Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-04
- **Final completion:** 2009-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2009-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423410, "A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00423410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*